Published: 9/22/2022 3:10:10 PM
Eevia Health offer organic plant extracts for food nutraceuticals, drinks, and cosmetics under different brands. The Company is at a stage where it aims to increase production capacity, focus on higher margin extracts, and develop new proprietary ingredients targeting eye disorders, which could be strong value drivers ahead. Having a broad product portfolio and high demand from customers, Eevia Health is entering a fast-growth phase, where an EBIT of EUR 4.8m is estimated in 2026. Based on an applied EV/EBIT multiple of 5x on estimated EBIT, and a discount rate of 14%, this yields an equity value per share of SEK 8.8 in a Base scenario. In conclusion, we see several drivers as well as market trends in Eevia’s favor, and where steps in the right direction should reduce the current valuation discount.
Link to the analysis